The AMD Experts
We’re on a mission to eliminate blindness caused by age-related macular degeneration (AMD). Our vision is bold but well within reach.
MacuLogix is the only company to equip eye care professionals with the technology, tools and education needed to identify and manage AMD patients early, before irreversible vision loss has occurred. We can help you deliver better patient care with the scientifically-validated, FDA 510(k)-cleared AdaptDx.
Help us save the eyesight of millions by making early functional testing for AMD a routine part of eye care for your aging patients.
The MacuLogix team is committed to empowering primary eye care professionals with the technology and tools needed to create AMD Centers of Excellence.
Bill McPhee, the President and CEO of MacuLogix, shares his personal story of why he joined the company and adopted its vision of eliminating blindness caused by AMD.
The AdaptDx is especially useful for optometrists and general ophthalmologists who see many patients with “normal” clinical exams, since it can detect subclinical AMD up to three years before clinical onset. With the AdaptDx, you will be in the front line in detecting these patients and will be able to carefully monitor and treat those with subclinical AMD.
Put Our Expertise to Work
Testing with AdaptDx
AdaptDx identifies impaired dark adaptation—the earliest warning sign of AMD.
Guiding AdaptDx Implementation
Each AdaptDx purchase is supported by our AMD Excellence Program™ to help you achieve your patient care and practice revenue goals.
Latest News & Upcoming EventsView More
This funding will be used to further expand the team and company infrastructure to support the growing sales and practice integration efforts of the AdaptDx automated dark adaptometer.
The value we bring to eye care professionals’ practices is what makes us truly stand out in the crowd. By Armond Dantino.
Practitioners can use the AdaptDx by Maculogix to test a patient’s dark adaptation, which can be a biomarker for AMD, according to Bill McPhee, CEO of Maculogix.